Intramuscular mast cell tumour in a dog

Shales, Chris; White, Rob

doi:10.1136/vr.e5024

Cited by 3 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In that study, decreased survival was found with a mitotic count (MC) > 4/10 high power field (HPF; 2.37 sq mm), infiltrative growth pattern and the presence of multinucleation. 3 Intramuscular MCT (IntraM MCT) have been reported previously 4,5 and in a case series of seven dogs; three dogs were treated with surgery alone and 3 dogs with surgery and adjuvant chemotherapy postsurgery; no recurrence or metastasis were reported with a follow-up of 7 months. 5 Surgery is currently the treatment of choice for dermal, SC, and IntraM MCT.…”

Section: Introductionmentioning

confidence: 97%

CT features of subcutaneous, intermuscular, and intramuscular mast cell tumors in dogs

Farmer

Poirier

Nykamp

et al. 2022

Vet Radiology Ultrasound

View full text Add to dashboard Cite

Surgical removal is the treatment of choice for subcutaneous (SC), intermuscular (InterM), and intramuscular (IntraM) mast cell tumors (MCTs). Advanced imaging (CT or MRI) is frequently used for presurgical planning, but InterM and IntraM MCTs can be difficult to identify and delineate on CT. Aims of the current retrospective, diagnostic accuracy, observer agreement study were to describe the imaging features of SC, InterM, and IntraM MCTs on CT and to assess the limitation of CT to identify the full local extent of the MCT. Inclusion criteria for the study were dogs with a cytologically or histologically diagnosed MCTs determined to be SC, InterM, or IntraM MCT based on histology and/or a CT scan performed in the gross disease setting.Two board-certified veterinary radiologists reviewed the CT images and recorded location, contrast enhancement pattern, and delineation between the normal and abnormal tissue. Sensitivity and specificity of CT for determining location (SC/InterM versus IntraM) was 85.71% and 55.56%, respectively, when compared to consensus location based on surgical pathology report/CT/MRI review. There was a low interrater agreement for delineation (kappa: 0.150 (−0.070 to 0.370) and measurement had a low/moderate correlation (rho: 0.4667 to 0.5792). Upon review by a surgical oncologist, CT findings were deemed insufficient for curative surgical planning in 13 of 16 due to inadequate definition of tumor depth, compartment boundary (fascial plane) or MCT margins. The use of CT for presurgical planning of SC/InterM/IntraM MCT dogs has limitations, especially when differentiating MCT from the adjacent muscle.

show abstract